Last reviewed · How we verify
Lecanemab treatment group
At a glance
| Generic name | Lecanemab treatment group |
|---|---|
| Sponsor | Cuibai Wei，Clinical Professor |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease (PHASE2)
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (PHASE2, PHASE3)
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (PHASE2, PHASE3)
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (PHASE2)
- An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
- Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
- Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lecanemab treatment group CI brief — competitive landscape report
- Lecanemab treatment group updates RSS · CI watch RSS
- Cuibai Wei，Clinical Professor portfolio CI